EP07.05. Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Haitao Ma
Meta Tag
Speaker Haitao Ma
Topic Early-Stage NSCLC: Pushing the Boundaries
oral EGFR tyrosine kinase inhibitor
EGFR mutations
postoperative adjuvant treatment
ground-glass opacity lesions
disease-free survival rate
adverse events
therapeutic effects
persistent GGO lesions
Powered By